Vascular Endothelial Growth Factor in Plasma and Pleural Effusion Is a Biomarker for Outcome After Bevacizumab plus Carboplatin-Paclitaxel Treatment for Non-small Cell Lung Cancer with Malignant Pleural Effusion.

@article{Tamiya2016VascularEG,
  title={Vascular Endothelial Growth Factor in Plasma and Pleural Effusion Is a Biomarker for Outcome After Bevacizumab plus Carboplatin-Paclitaxel Treatment for Non-small Cell Lung Cancer with Malignant Pleural Effusion.},
  author={Motohiro Tamiya and Akihiro Tamiya and Tomomi Yasue and Keiko Nakao and Naoki Omachi and Takayuki Shiroyama and Eriko Tani and Masanari Hamaguchi and Naoko Morishita and Hidekazu Suzuki and Norio Okamoto and Kyoichi Okishio and Tomoya Kawaguchi and Shinji Atagi and Tomonori Hirashima},
  journal={Anticancer research},
  year={2016},
  volume={36 6},
  pages={2939-44}
}
AIM Malignant effusion is associated with high serum and plasma levels of vascular endothelial growth factor (VEGF). There are no biomarkers of outcome for bevacizumab treatment in patients with malignant pleural effusion (MPE). We previously reported that carboplatin-paclitaxel plus bevacizumab was effective for patients with advanced non-squamous non-small cell lung cancer (NSCLC) and MPE, although we did not evaluate the relationship between treatment outcomes and plasma or pleural effusion… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS